Research Topics
| G R BailieSummaryAffiliation: Albany College of Pharmacy Country: USA Publications
| Collaborators
|
Detail Information
Publications
Hypersensitivity reactions and deaths associated with intravenous iron preparationsGeorge R Bailie
Albany Nephrology Pharmacy ANephRx Group, Albany, NY, USA
Nephrol Dial Transplant 20:1443-9. 2005..We used the US Food and Drug Administration's Freedom of Information (FOI) surveillance database to compare the type 1 AE profiles for the three intravenous iron preparations available in the United States...
Patterns of medication use in the RRI-CKD study: focus on medications with cardiovascular effectsGeorge R Bailie
Albany Nephrology Pharmacy Group, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA
Nephrol Dial Transplant 20:1110-5. 2005..We report on prescription data collected as part of a multicentre longitudinal study in patients with CKD, with a focus on medications with cardiovascular or cardioprotective effects...
From dialysis outcomes quality initiative to kidney disease outcomes quality initiative: new clinical practice guidelines in nephrology--what the practicing pharmacist needs to knowGeorge R Bailie
Albany College of Pharmacy, Albany, New York 12208, USA
Pharmacotherapy 24:551-7. 2004..This article provides a broad overview to the background of the development of CPGs in nephrology and the methodology used. Subsequent articles will identify in some detail current and pending CPGs that relate to pharmacotherapy...
Therapeutic dilemmas in the management of peritonitisGeorge R Bailie
Albany Nephrology Pharmacy Group, Albany College of Pharmacy, New York, USA
Perit Dial Int 25:152-6. 2005
Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney diseaseGeorge R Bailie
Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
Pharmacotherapy 25:491-502. 2005..Also discussed are the association of level of kidney function with systemic complications that develop during CKD, and the risk of loss of kidney function and development of cardiovascular disease in CKD...
Analysis of medication use in peritoneal dialysis patients in two unitsGeorge R Bailie
Albany College of Pharmacy, Albany, New York, USA
Perit Dial Int 25:287-90. 2005
Clinical practice guidelines for bone metabolism and disease in chronic kidney disease: an overviewGeorge R Bailie
Albany Nephrology Pharmacy ANephRx Group, Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208, USA
Pharmacotherapy 25:1687-707. 2005..The problems and sequelae of soft-tissue calcification are discussed, and recommendations are provided for reducing the associated morbidity and mortality...
Large variations in prescriptions of gastrointestinal medications in hemodialysis patients on three continents: the Dialysis Outcomes and Practice Patterns Study (DOPPS)George R Bailie
Albany College of Pharmacy, Albany, New York 12208, USA
Hemodial Int 10:180-8. 2006..5 g/dL. Prescription of GI medications was associated with many comorbidities and use of several medications. Extreme variability of prescription patterns suggests that there is no standard approach in treatment practices...
Sexual dysfunction in dialysis patients treated with antihypertensive or antidepressive medications: results from the DOPPSGeorge R Bailie
Albany Nephrology Pharmacy ANephRx Group, Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208, USA, and Department of Internal Medicine, Koga Redcross Hospital, Ibaraki, Japan
Nephrol Dial Transplant 22:1163-70. 2007..The relationship between medication prescription and sexual dysfunction (SD) in dialysis patients is unclear...
Parenteral iron use in the management of anemia in end-stage renal disease patientsG R Bailie
Nephrology Pharmacy Associates, Inc, Ann Arbor, MI, USA
Am J Kidney Dis 35:1-12. 2000..Currently available data suggest that iron sucrose and iron gluconate may have diminished adverse effect profiles when compared with iron dextran. Additional clinical experience will establish the role for these new iron products...
Analgesic prescription patterns among hemodialysis patients in the DOPPS: potential for underprescriptionGeorge R Bailie
Albany College of Pharmacy, Albany, New York 12208, USA
Kidney Int 65:2419-25. 2004..Dialysis patients require special consideration regarding analgesics, given their altered pharmacokinetic and pharmacodynamic profiles and increased potential for adverse reactions...
HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patientsNancy A Mason
College of Pharmacy, University of Michigan, College of Pharmacy, Ann Arbor, MI 48109 1065, USA
Am J Kidney Dis 45:119-26. 2005..This study examined statin prescription patterns and assessed the relationship between statin prescription and clinical outcomes in hemodialysis (HD) patients...
Erythropoietin and iron use in peritoneal dialysis patients. Report from the 1997 HCFA end-stage renal disease core indicators projectG R Bailie
Center for Clinical Measurement and Improvement, Health Care Financing Administration, Albany, NY, USA
Am J Kidney Dis 33:1187-9. 1999..It is concluded that there could be improvement in the epoetin alfa and iron management in many patients...
Comparative review of the pharmacokinetics of vitamin D analoguesGeorge R Bailie
Albany College of Pharmacy, Albany, New York, USA
Semin Dial 15:352-7. 2002..More studies are warranted to determine the disposition of the vitamin D analogues, especially in selected populations such as pediatric and geriatric dialysis patients...
Diuretic use, residual renal function, and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Pattern Study (DOPPS)Jennifer L Bragg-Gresham
Arbor Research Collaborative for Health, formerly University Renal Research and Education Association, Ann Arbor, MI, USA
Am J Kidney Dis 49:426-31. 2007..Information about residual renal function (RRF) and outcomes associated with practices of diuretic use in patients with end-stage renal disease is not available worldwide...
Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysisRowland J Elwell
Albany Nephrology Pharmacy Group, Department of Pharmacy Practice, Albany College of Pharmacy, Albany, New York 12208 3492, USA
Perit Dial Int 25:380-6. 2005..This study determined the pharmacokinetics of intraperitoneal (IP) cefepime in automated peritoneal dialysis (APD) patients...
Hepatitis B vaccination: addressing a drug-related problem in hemodialysis outpatients with a collaborative initiativeRowland J Elwell
Albany College of Pharmacy, Albany, NY, USA
Nephrol Nurs J 30:310-3. 2003..CONCLUSION: Given CDC guidelines, HBV vaccine should be offered to all HD patients. This initiative demonstrates that with concerted effort all consenting HD patients can receive HBV vaccination, thereby addressing an important DRP...
Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: a retrospective cohort studyRowland J Elwell
Department of Pharmacy Practice, Albany College of Pharmacy Albany, New York 12208, USA
Pharmacotherapy 23:1558-63. 2003..To assess the influence of various clinical factors on antibody production induced by hepatitis B vaccine in patients receiving hemodialysis up to 24 months after vaccination...
Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125Harold J Manley
School of Pharmacy, University of Missouri, Kansas City, MO, USA
Ann Pharmacother 38:2035-40. 2004..Human peritoneal mesothelial cells (HPMCs) may be affected by high IP cefazolin and ceftazidime concentrations. Peritoneal dialysate cancer antigen-125 (CA-125) appearance rate can be used to measure HPMC damage...
Medication-related problems in ambulatory hemodialysis patients: a pooled analysisHarold J Manley
Albany College of Pharmacy, Albany, NY 12208, USA
Am J Kidney Dis 46:669-80. 2005..We conducted a pooled analysis to gain additional insight into the frequency, type, and severity of medication-related problems and extrapolated the data to the entire US HD population...
Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzersK M Sowinski
Department of Pharmacy Practice, School of Pharmacy and Pharmacal Sciences, Purdue University, Indianapolis, IN 46202 2879, USA
Am J Kidney Dis 37:766-76. 2001..Cefazolin doses of 15 or 20 mg/kg after each hemodialysis session maintained adequate serum concentrations throughout a 2- or 3-day interdialytic period regardless of hemodialyzer type...
Rosiglitazone is associated with mortality in chronic hemodialysis patientsSylvia P B Ramirez
Arbor Research Collaborative for Health, 315 W Huron, Ann Arbor, MI 48103, USA
J Am Soc Nephrol 20:1094-101. 2009..Our practice-based findings suggest significant associations of rosiglitazone use with higher cardiovascular and all-cause mortality among hemodialysis patients with diabetes...
Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemiaGeorge R Bailie
Albany College of Pharmacy and Health Sciences, Albany, New York, USA
Hemodial Int 14:47-54. 2010..Administration of FCM (15 mg/kg, maximum of 1000 mg) over 15 minutes was well tolerated and associated with minimal risk of adverse reactions in patients with iron deficiency anemia...
Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysisChaim Charytan
New York Hospital of Queens, Flushing, NY, USA
Nephron Clin Pract 100:c55-62. 2005..Iron sucrose, given weekly as 200 mg IV push over 5 min is an effective and safe anemia treatment in this population...
Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indicationsGeorge R Bailie
Albany Nephrology Pharmacy ANephRx Group, Albany, New York, USA
Arzneimittelforschung 60:386-98. 2010..No safety concerns have been identified in breastfed infants of mothers receiving FCM. FCM is, therefore, an effective and well-tolerated option in the treatment of IDA...
Safety of propoxyphene in dialysis patientsGeorge R Bailie
Semin Dial 15:375. 2002
Analysis of renal bone disease treatment in dialysis patientsCurtis A Johnson
Renal Network of the Upper Midwest, ESRD Network 11, St Paul, MN, USA
Am J Kidney Dis 39:1270-7. 2002..There is opportunity to improve renal osteodystrophy protocols in Network 11 and reinforce potential hazards of sustained hyperphosphatemia and hyperparathyroidism...
Treatment of peritonitis in APD: pharmacokinetic principlesHarold J Manley
University of Missouri Kansas City, School of Pharmacy, Kansas City, Missouri 64108, USA
Semin Dial 15:418-21. 2002..Knowledge of antibiotic disposition in PD patients will assist clinicians in appropriate IP antibiotic dose selection and prevention of dose-related adverse effects...
Peritoneal dialysis-related infections recommendations: 2005 updateBeth Piraino
University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
Perit Dial Int 25:107-31. 2005
Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolinHarold J Manley
School of Pharmacy, University of Missouri Kansas City, Kansas City, Missouri 64108, USA
Perit Dial Int 23:469-74. 2003..To determine the impact of dialysate flow rate (DFR) on cefazolin pharmacokinetics (PK) in peritoneal dialysis (PD) patients...
Iron and the anaemia of chronic disease: a review and strategic recommendationsIvor Cavill
Medical School, Cardiff University, UK
Curr Med Res Opin 22:731-7. 2006..Improvement in the management of anaemia requires a fundamental change of attitude from healthcare professionals...
Gentamicin pharmacokinetics during slow daily home hemodialysisHarold J Manley
University of Missouri Kansas City, Kansas City 64108, USA
Kidney Int 63:1072-8. 2003..Slow daily home (SDH) hemodialysis (7 to 9 hours a day/6 days a week) use is increasing due to benefits observed with increased hemodialysis. We determined gentamicin pharmacokinetics for SDH hemodialysis patients...
Delayed absorption and postdialysis rebound in a case of acute methanol poisoningRowland J Elwell
Am J Emerg Med 22:126-7. 2004
